Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

As 2025 approaches, the healthcare landscape is undergoing rapid transformation. Rising healthcare utilization, escalating ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...